Bicara director granted options on 19,475 shares

Bicara Therapeutics Inc. director Kate Haviland received a stock option grant giving her the right to buy 19,475 shares of common stock at an exercise price of $20.56 per share.

Rhea-AI Filing Summary

Bicara Therapeutics Inc. director Kate Haviland received a stock option grant giving her the right to buy 19,475 shares of common stock at an exercise price of $20.56 per share. These options were granted at no cost and represent a compensation award rather than an open-market purchase.

The 19,475 underlying shares vest on the earlier of June 9, 2027 or the date of the company’s next Annual Meeting of Stockholders, provided she continues serving as a director through that vesting date. Following this grant, her reported option holdings from this award total 19,475 shares.

Insider Trade Summary

Grant/Award: 19,475 shares

Grant/Award 1 txn

Insider Haviland Kate

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,475	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 19,475 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Key Figures

Option grant size: 19,475 shares Exercise price: $20.56 per share Post-grant option holdings: 19,475 derivative shares +2 more

5 metrics

Option grant size 19,475 shares Stock options awarded to director Kate Haviland

Exercise price $20.56 per share Conversion or exercise price of stock options

Post-grant option holdings 19,475 derivative shares Total shares underlying options following this transaction

Option expiration June 9, 2036 Reported expiration date of the stock options

Vesting date trigger June 9, 2027 or next annual meeting Earlier of these dates, subject to continued service

Key Terms

Stock Option (Right to Buy), conversion or exercise price, vest, Annual Meeting of Stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

conversion or exercise price financial

"conversion_or_exercise_price: "20.5600""

vest financial

"The shares underlying this stock option vest upon the earlier of"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Annual Meeting of Stockholders regulatory

"the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bicara Therapeutics (BCAX) director Kate Haviland receive in this Form 4?

Director Kate Haviland received a stock option grant for 19,475 shares. The options give her the right to buy Bicara Therapeutics common stock as part of her compensation, rather than reflecting an open-market share purchase or sale.

What is the exercise price of Kate Haviland’s Bicara Therapeutics (BCAX) stock options?

The stock options have an exercise price of $20.56 per share. This is the price she would pay to convert the options into Bicara Therapeutics common stock once the options have vested, assuming she chooses to exercise them.

How many Bicara Therapeutics (BCAX) shares are covered by the new stock option grant?

The grant covers options over 19,475 shares of Bicara Therapeutics common stock. These options were reported as a single derivative transaction and represent a new award rather than a purchase of already outstanding shares.

When do Kate Haviland’s Bicara Therapeutics (BCAX) stock options vest?

The options vest on the earlier of June 9, 2027 or the date of Bicara Therapeutics’ next Annual Meeting of Stockholders. Vesting is conditioned on her continued service as a director through the applicable vesting date.

Is Kate Haviland’s Bicara Therapeutics (BCAX) Form 4 transaction a market buy or sell?

No, the Form 4 reports a grant of stock options, not a market trade. The transaction is classified as a grant or award acquisition, meaning it reflects equity compensation rather than an open-market purchase or sale of shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Haviland Kate

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20.56	06/09/2026		A		19,475		(1)	06/09/2036	Common Stock	19,475	$0	19,475	D

Explanation of Responses:

1. The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Remarks:

	/s/ Ryan Cohlhepp, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)